Nektar Therapeutics
NASDAQ:NKTR
Nektar Therapeutics
Gross Profit
Nektar Therapeutics
Gross Profit Peer Comparison
Competitive Gross Profit Analysis
Latest Figures & CAGR of Competitors
Company | Gross Profit | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Nektar Therapeutics
NASDAQ:NKTR
|
Gross Profit
$54.9m
|
CAGR 3-Years
-19%
|
CAGR 5-Years
-46%
|
CAGR 10-Years
-7%
|
|
Johnson & Johnson
NYSE:JNJ
|
Gross Profit
$59.6B
|
CAGR 3-Years
2%
|
CAGR 5-Years
2%
|
CAGR 10-Years
2%
|
|
Bristol-Myers Squibb Co
NYSE:BMY
|
Gross Profit
$34.6B
|
CAGR 3-Years
2%
|
CAGR 5-Years
16%
|
CAGR 10-Years
11%
|
|
Pfizer Inc
NYSE:PFE
|
Gross Profit
$38.8B
|
CAGR 3-Years
55%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
-1%
|
|
Merck & Co Inc
NYSE:MRK
|
Gross Profit
$46B
|
CAGR 3-Years
17%
|
CAGR 5-Years
9%
|
CAGR 10-Years
6%
|
|
Eli Lilly and Co
NYSE:LLY
|
Gross Profit
$28.8B
|
CAGR 3-Years
14%
|
CAGR 5-Years
11%
|
CAGR 10-Years
5%
|
See Also
What is Nektar Therapeutics's Gross Profit?
Gross Profit
54.9m
USD
Based on the financial report for Mar 31, 2024, Nektar Therapeutics's Gross Profit amounts to 54.9m USD.
What is Nektar Therapeutics's Gross Profit growth rate?
Gross Profit CAGR 10Y
-7%
Over the last year, the Gross Profit growth was -16%. The average annual Gross Profit growth rates for Nektar Therapeutics have been -19% over the past three years , -46% over the past five years , and -7% over the past ten years .